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Inhibition of Triggering Receptor 
Expressed on Myeloid Cells 1 Ameliorates 
Inflammation and Macrophage and 
Neutrophil Activation in Alcoholic Liver 
Disease in Mice
David Tornai,1 Istvan Furi,1 Zu T. Shen,2 Alexander B. Sigalov,2 Sahin Coban,1 and Gyongyi Szabo1
Alcoholic liver disease (ALD) is characterized by macrophage and neutrophil leukocyte recruitment and activation in 
the liver. Damage- and pathogen-associated molecular patterns contribute to a self-perpetuating proinflammatory 
state in ALD. Triggering receptor expressed on myeloid cells 1 (TREM-1) is a surface receptor that amplifies 
inf lammation induced by toll-like receptors (TLRs) and is expressed on neutrophils and monocytes/macrophages. We 
hypothesized that TREM-1 signaling contributes to proinflammatory pathway activation in ALD. Using an in vivo 
ALD model in mice, we tested the effects of ligand-independent TREM-1 inhibitory peptides that were formulated 
into human high-density lipoprotein (HDL)-mimicking complexes GF9-HDL and GA/E31-HDL. As revealed 
in vitro, macrophages endocytosed these rationally designed complexes through scavenger receptors. A 5-week alcohol 
feeding with the Lieber-DeCarli diet in mice resulted in increased serum alanine aminotransferase (ALT), liver stea-
tosis, and increased proinflammatory cytokines in the liver. TREM-1 messenger RNA (mRNA) expression was sig-
nificantly increased in alcohol-fed mice, and TREM-1 inhibitors significantly reduced this increase. TREM-1 
inhibition significantly attenuated alcohol-induced spleen tyrosine kinase (SYK) activation, an early event in both 
TLR4 and TREM-1 signaling. The TREM-1 inhibitors significantly inhibited macrophage (epidermal growth factor-
like module-containing mucin-like hormone receptor-like 1 [F4/80], clusters of differentiation [CD]68) and neutro-
phil (lymphocyte antigen 6 complex, locus G [Ly6G] and myeloperoxidase [MPO]) markers and proinflammatory 
cytokines (monocyte chemoattractant protein 1 [MCP-1], tumor necrosis factor α [TNF-α], interleukin-1β [IL-1β], 
macrophage inflammatory protein 1α [MIP-1α] at the mRNA level compared to the HDL vehicle. Administration 
of TREM-1 inhibitors ameliorated liver steatosis and early fibrosis markers (α-smooth muscle actin [αSMA] and 
procollagen1α [Pro-Col1α]) at the mRNA level in alcohol-fed mice. However, the HDL vehicle also reduced serum 
ALT and some cytokine protein levels in alcohol-fed mice, indicating HDL-related effects. Conclusion: HDL-delivered 
novel TREM-1 peptide inhibitors ameliorate early phases of inf lammation and neutrophil and macrophage recruit-
ment and activation in the liver and attenuate hepatocyte damage and liver steatosis. TREM-1 inhibition represents 
a promising therapeutic approach for further investigations in ALD. (Hepatology Communications 2019;3:99-115).
ALD has been a long-standing public health problem globally, yet the pathomechanisms leading to alcoholic hepatitis, a severe and often deadly form of the disease, are only partially understood. The direct effects of alcohol and its metabolites on hepatocytes result in steatosis and 
Abbreviations: ACC1, acetyl-coenzyme A carboxylase 1; ADRP, perilipin-2; ALD, alcoholic liver disease; ALT, alanine aminotransferase; Apo 
A-1, apolipoprotein A-I; BLT-1, blocker of lipid transport 1; CD, clusters of differentiation; CPT1A, carnitine palmitoyltransferase 1A; DAMP, 
damage-associated molecular pattern; ELISA, enzyme-linked immunosorbent assay; EtOH, ethanol; F4/80, epidermal growth factor-like module-
containing mucin-like hormone receptor-like 1; H&E, hematoxylin and eosin; HDL, high-density lipoprotein; IHC, immunohistochemistry; IL, 
interleukin; LPS, lipopolysaccharide; Ly6G, lymphocyte antigen 6 complex, locus G; MCAD, medium-chain acyl-coenzyme A dehydrogenase; 
MCP-1, monocyte chemoattractant protein 1; MIP-1α, macrophage inflammatory protein 1α; MPO, myeloperoxidase; mRNA, messenger RNA; 
p-SYK, activated phosphorylated-SYK; PAMP, pathogen-associated molecular pattern; PCR, polymerase chain reaction; PF, pair-fed; POPC, 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; PPARα, peroxisome proliferator-activated receptor α; Pro-Col1α, procollagen-1α; RANTES, 
regulated on activation, normal T cell expressed, and secreted; rho B, rhodamine B; SR, scavenger receptor; SREBF1, sterol regulatory element 
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endoplasmic reticulum stress and trigger release of 
damage-associated molecular patterns (DAMPs). In 
addition, excessive and/or chronic alcohol consump-
tion disrupts the gut barrier function and changes the 
gut microbiome, leading to increased levels of micro-
bial pathogen-associated molecular patterns (PAMPs) 
in the circulation. PAMPs from portal circulation and 
locally released DAMPs provide proinflammatory 
signals in the liver for activation of resident Kupffer 
cells and recruitment of activated macrophages and 
neutrophil leukocytes from the bone marrow.(1,2) 
Increased lipopolysaccharide (LPS) levels in animal 
models of ALD and in patients with alcoholic hepati-
tis contribute to macrophage and neutrophil activation 
and proinflammatory cascade activation by theTLR4 
receptor complex. Cytokines induced by PAMPs and 
DAMPs contribute to a self-perpetuating proinflam-
matory state that characterizes alcoholic hepatitis.(3)
TREM-1 is an activating receptor complex that 
is expressed on neutrophils and monocytes/macro-
phages and amplifies TLR signaling.(4) It has been 
shown that TREM-1 can amplify TLR4-mediated as 
well as TLR2-mediated proinflammatory signals.(5,6) 
The expression and function of TREM-1 has been 
indicated in various inflammatory diseases, including 
sepsis, cancer, retinopathy of prematurity (ROP), ath-
erosclerosis, and experimental colitis.(7-9) Expression 
of TREM-1 in hepatic stellate cells was proposed as a 
prognostic factor in hepatitis B-related hepatocellular 
carcinoma (HCC), and TREM-1-mediated Kupffer 
cell activation was found in HCC.(10,11) Little is 
known about the role of TREM-1 in ALD. Here, we 
hypothesized that inhibition of TREM-1 will ame-
liorate inflammation and liver damage in ALD, given 
the known role of TREM-1 in myeloid cell activation 
and amplification of proinflammatory signaling.
Despite some recent evidence that peptidoglycan 
recognition protein 1 (PGLYRP1) may potentially 
act as a ligand for TREM-1,(12) the actual TREM-1 
ligand(s) and molecular mechanisms of TREM-1 sig-
naling are not well understood, impeding the devel-
opment of clinically relevant inhibitors of TREM-1. 
Previously, we used our signaling chain homo-oligomer-
ization (SCHOOL) model of TREM-1 signaling(13,14) 
binding transcription factor 1; SYK, spleen tyrosine kinase; TLR, toll-like receptor; TNF-α, tumor necrosis factor α; TREM-1, triggering receptor 
expressed on myeloid cells 1; UMMS, University of Massachusetts Medical School.
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to rationally design a novel, first-in-class, TREM-1 
inhibitory peptide (GF9) and demonstrated that GF9 
suppresses inflammation in vitro and in vivo and 
exhibits therapeutic effects in animal models of sepsis, 
cancer, rheumatoid arthritis, and ROP.(15-18) We also 
significantly improved peptide half-life and its targeted 
delivery to macrophages in vitro and in vivo by formu-
lation of the GF9 peptide sequence into self-assem-
bling lipopeptide complexes that mimic human HDLs 
but in contrast to native HDLs are endocytosed by 
macrophages.(15-20) These complexes have either GF9 
and two modified peptides with sequences correspond-
ing to those of helices 4 (H4 [or PE22]) and 6 (H6 
[or PA22]) of the major HDL protein apolipoprotein 
(apo) A-I (GF9-HDL) or an equimolar mixture of 
31 amino acid-long peptides GA31 and GE31, with 
sequences corresponding to those of GF9 and either 
PA22 or PE22, respectively (GA/E31-HDL). By com-
bining these sequences, GA31 and GE31 were shown 
to assist in the self-assembly of HDLs, target HDLs to 
macrophages, and inhibit TREM-1 in vivo.(15-17)
In the present study, we investigated the role of 
TREM-1 in ALD and the potential therapeutic effect 
of the TREM-1 inhibitory GF9-HDL and GA/
E31-HDL formulations in the Lieber-DeCarli ALD 
mouse model.(21)
Materials and Methods
reagents anD Cells
The murine macrophage J774A.1 cell line was pur-
chased from ATCC (Manassas, VA). Cytochalasin D 
was purchased from MP Biomedicals (Solon, OH). 
Blocker of lipid transport 1 (BLT-1) was purchased 
from Calbiochem (Torrey Pines, CA). Sodium cho-
late, cholesteryl oleate, fucoidan, and other chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO). 
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1,2-dimyristoyl-sn-glycero-3-phosphoe-
thanolamine-N-(lissamine rhodamine B sulfonyl) 
(rho B), and cholesterol were purchased from Avanti 
Polar Lipids (Alabaster, AL).
peptiDe syntHesis
The following synthetic peptides were ordered 
from Bachem (Torrance, CA): one 9-mer pep-
tide, GFLSKSLVF (human TREM-1213-221, GF9); 
two 22-mer methionine sulfoxidized peptides, 
PYLDDFQKKWQEEM(O)ELYRQKVE (H4) and 
PLGEEM(O)RDRARAHVDALRTHLA (H6), 
which correspond to human apo A-I helices 4 
(apo A-I123-144) and 6 (apo A-I167-188), respec-
tively; and two 31-mer methionine sulfoxidized 
peptides, GFLSKSLVFPYLDDFQKKWQEEM(O)
ELYRQKVE (GE31) and GFLSKSLVFPLG-
EEM(O)RDRARAHVDALRTHLA (GA31).
lipopeptiDe CompleXes
HDL-mimicking lipopeptide complexes of spher-
ical morphology that contained either GF9 and an 
equimolar mixture of PE22 and PA22 (GF9-HDL) 
or an equimolar mixture of GA31 and GE31 (GA/
E31-HDL) were synthesized using the sodium 
cholate dialysis procedure, purified, and charac-
terized as described.(16-18,22) For GF9-HDL, the 
initial molar ratio was 125:6:2:3:1:210, correspond-
ing to POPC:cholesterol:cholesteryl oleate:GF9:apo 
A-I:sodium cholate, respectively, where apo A-I was an 
equimolar mixture of PE22 and PA22. For GA/E31-
HDL, the initial molar ratio was 125:6:2:1:210, corre-
sponding to POPC:cholesterol:cholesteryl oleate:GA/
E31:sodium cholate, respectively, where GA/E31 was 
an equimolar mixture of GA31 and GE31.
IN VITRO maCropHage uptaKe 
oF gF9-HDl anD  
ga/e31-HDl
A quantitative in vitro macrophage assay of endo-
cytosis of rho B-labeled HDL-mimicking lipopep-
tide complexes by J774 macrophage was performed 
as described.(18-20) Briefly, BALB/c murine macro-
phage J774A.1 cells (ATCC) were cultured at 37°C 
with 5% CO2 in Dulbecco’s modified Eagle’s medium 
(Cellgro Mediatech, Manassas, VA) with 2 mM gluta-
mine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 
and 10% heat-inactivated fetal bovine serum (Cellgro 
Mediatech) and grown to approximately 90% conflu-
ency in 12-well tissue culture plates (Corning Costar, 
Corning, NY). After reaching target confluency, cells 
were incubated for 1 hour in medium with or without 
fucoidan (400 μg/mL), BLT-1 (10 μM), or cytochala-
sin D (40 μM). Cells were subsequently incubated for 
4 hours and 22 hours at 37°C in medium containing 
2 μM of rho B-labeled GF9-HDL or GA/E31-HDL 
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(as calculated for rho B). Cells were washed twice using 
phosphate-buffered saline and lysed using Passive 
Lysis Buffer (Promega, Madison, WI). Rho B fluores-
cence was measured in the lysates with 544-nm exci-
tation and 590-nm emission filters, using a Fluoroscan 
Ascent CF fluorescence microplate reader (Thermo 
Labsystems, Vantaa, Finland). Protein concentrations 
in the lysates were measured using Bradford reagent 
(Sigma-Aldrich) and an MRX microplate reader 
(Dynex Technologies, Chantilly, VA) according to the 
manufacturer’s recommended protocol.
animals
C57BL/6 female mice (10- to 12-week-old) were 
purchased from the Jackson Laboratory (Bar Harbor, 
ME) and housed at the University of Massachusetts 
Medical School (UMMS) animal facility. All ani-
mals received humane care in accordance with pro-
tocols approved by the UMMS Institutional Animal 
Use and Care Committee. Mice (n = 6-9/group) were 
acclimated to a Lieber-DeCarli liquid diet of 5% eth-
anol (EtOH) (volume [vol]/vol) over a period of 1 
week, then maintained on the 5% diet for 4 weeks. 
Pair-fed (PF) control mice were fed a calorie-matched 
dextran-maltose diet. All animals had unrestricted 
access to water throughout the entire experimental 
period. In treated groups, mice were intraperitone-
ally treated 5 days/week with vehicle (empty HDL) 
or the TREM-1 inhibitory formulations GF9-HDL 
(2.5 mg of GF9/kg) or GA/E31-HDL (4 mg equiv-
alent of GF9/kg) (SignaBlok, Shrewsbury, MA) from 
the first day on a 5% EtOH diet. At the end of all ani-
mal experiments, cheek blood samples were collected 
in serum collection tubes (BD Biosciences, San Jose, 
CA) and processed within an hour. After blood col-
lections, mice were euthanized and liver samples were 
harvested and stored at −80°C until further analysis.
total protein isolation 
From liVer
Total protein was extracted from liver samples 
using radio immunoprecipitation assay buffer (BP-
115; Boston BioProducts) supplemented with protease 
inhibitor cocktail tablets (11836153001; Roche) and 
Phospho Stop phosphatase inhibitor (04906837001; 
Roche). Cell debris was removed from cell lysates by 
10 minutes centrifugation at 12,000 rpm.
BioCHemiCal assays anD 
CytoKines
Serum ALT levels were determined by the kinetic 
method using commercially available reagents from 
Teco Diagnostics (Anaheim, CA). Cytokine levels were 
measured in serum samples, and whole-liver lysates 
were diluted in assay diluent following the manufac-
turer’s instructions. Specific anti-mouse enzyme-linked 
immunosorbent assay (ELISA) kits were used for the 
quantification of MCP-1, TNF-α (BioLegend Inc., San 
Diego, CA), and IL-1β (R&D Systems, Minneapolis, 
MN) levels. For normalization, the total protein con-
centration of the whole-liver lysate was determined 
using the Pierce bicinchoninic acid protein assay.
Western Blot analysis
Whole-liver proteins were boiled in Laemmli’s 
buffer. Samples were resolved in 10% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis gel under 
reducing conditions, using a Tris-glycine buffer system; 
resolved proteins were transferred onto a nitrocellu-
lose membrane. SYK proteins were detected by spe-
cific primary antibodies (SYK, 2712 [Cell Signaling]; 
phospho-SYKY525/526, ab58575 [Abcam]) followed by 
an appropriate secondary horseradish peroxidase-con-
jugated immunoglobulin G antibody from Santa Cruz 
Biotechnology. β-actin, detected by an ab49900 anti-
body (Abcam), was used as a loading control. The spe-
cific immunoreactive bands of interest were visualized 
by chemiluminescence (Bio-Rad Laboratories) using 
the Fujifilm LAS-4000 luminescent image analyzer.
rna eXtraCtion anD 
QuantitatiVe real-time 
polymerase CHain reaCtion 
analysis
Total RNA was extracted using the Qiagen 
RNeasy kit (Qiagen) according to the manufacturer’s 
instructions with on-column deoxyribonuclease treat-
ment. RNA was quantified using a Nanodrop 2000 
spectrophotometer (Thermo Fisher Scientific), and 
complementary DNA synthesis was performed using 
the iScript Reverse Transcription Supermix (Bio-Rad 
Laboratories) and 1 µg total RNA. Real-time quan-
titative polymerase chain reaction (PCR) was per-
formed using Bio-Rad iTaq Universal SYBR Green 
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Supermix and a CFX96 real-time detection system 
(Bio-Rad Laboratories). Relative gene expression was 
calculated by the comparative ∆∆Ct method. The 
expression level of target genes was normalized to the 
housekeeping gene 18S ribosomal RNA in each sam-
ple, and the fold change in the target gene expression 
among experimental groups was expressed as a ratio. 
Primers were synthesized by IDT, Inc.; the sequences 
are listed in Table 1.
liVer HistopatHology
Sections of formalin-fixed paraffin-embedded liver 
specimens from mice were stained with hematoxylin 
and eosin (H&E) or F4/80 (MF48000; Thermo Fisher 
Scientific) and MPO (ab9535; Abcam) antibodies 
for immunohistochemistry (IHC). The fresh-frozen 
samples were stained with Oil Red O at the UMMS 
Diabetes and Endocrinology Research Center histol-
ogy core facility.
statistiCal analysis
All statistical analyses were performed using 
GraphPad Prism 7.02 (GraphPad Software Inc.). 
Significance levels were determined using one-way 
analysis of variance followed by a post-hoc test for mul-
tiple comparisons. Data are shown as mean ± SEM, 
and differences were considered statistically signifi-
cant when P ≤ 0.05. 
Results
BloCKaDe oF trem-1  
signaling reDuCes tHe 
eXpression oF inFlammation-
assoCiateD genes in alD in 
miCe
Previous reports showed that TREM-1 activation 
leads to the expression and release of proinflamma-
tory cytokines and chemokines through nuclear fac-
tor κB activation, which also regulates the expression 
of TREM-1, providing a positive feedback loop on 
the expression of the receptor.(4) Proinflammatory 
cytokine expression is increased in ALD(1-3,23,24); 
therefore, we hypothesized that TREM-1 signaling 
contributes to the amplification of proinflammatory 
pathways in ALD. To evaluate this hypothesis, first 
we tested whole-liver mRNAs of EtOH-fed and PF 
mice with or without treatment with two different 
taBle 1. seQuenCes oF primers useD in tHis stuDy
Mouse Primers
Primers
Forward Sequence 5′ to 3′ Reverse Sequence 5′ to 3′
18s GTA ACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
TREM-1 TCCTATTACAAGGCTGACAGAGCGTC AAGACCAGGAGAGGAAACAACCGC
TNF-α CACCAC CATCAA GGACTC AA AGGCAACCTGACCAC TCTCC
MCP-1 CAGGTCCCT GTCATGCTTCT CAGGTCCCTGTC ATGCTTCT
IL-1β CTTTGAAGTTGACGGACCC TGAGTGATACTGCCTGCCTG
MPO CATCCAACCCTTCATGTTCC CTGGCGATTCAGTTTGG
LY6G TGCGTTGCTCTGCTGGAGATAGA CAGAGTAGTGGGGCAGATGG
F4/80 TGCATCTAGCAATGGACAGC GCCTTCTGGATCCATTTGAA
CD68 TGTCTGATCTTGCTAGGACCG GAGAGTAACGGCCTTTTTGTG
Pro-Col1α GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGG
α-SMA GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA
ACC1 AGCAGATCCGCAGCTTG ACCTCTGCTCGCTGAGTGC
MIP-1α TTCTCTGTACCATGACACTCTGC GCATTAGCTTCAGATTTACGGGT
RANTES GCTGCTTTGCCTACCTCTCC TCGAGTGACAAACACGACTGC
ADRP CTGTCTACCAAGCTCTGCTC CGATGCTTCTCTTCCACTCC
PPARα AACATCGAGTGTCGAATATGTGG AGCCGAATAGTTCGCCGAAAG
SREBF1 GCTTCTTACAGCACAGCAACC TTTCATGCCCTCCATAGACAC
CPT1A CCAGGCTACAGTGGGACATT GAACTTGCCCATGTCCTTGT
MCAD GATCGCAATGGGTGCTTTTGATAGAA AGCTGATTGGCAATGTCTCCAGCAAA
tornai et al. Hepatology CommuniCations, January 2019
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TREM-1 inhibitory formulations and a vehicle control 
in a 5-week alcohol administration model of ALD in 
mice.(25) We found that mRNA levels of TREM-1 and 
MCP-1 were significantly increased in livers of alco-
hol-fed mice compared to PF controls (Fig. 1A,B). In 
contrast, in mice treated with the TREM-1 inhibitors, 
both GF9-HDL and GA/E31-HDL inhibited alco-
hol-related changes in TREM-1; in addition, MCP-1 
mRNA levels corresponded to those of the PF con-
trols (Fig. 1A,B). Although induction of TNF-α and 
IL-1ß in alcohol-fed mice did not reach statistical sig-
nificance compared to PF controls, TREM-1 block-
ade by GF9-HDL resulted in a significant inhibition 
of TNF-α mRNA in the alcohol-fed mice compared 
to vehicle treatment (Fig. 1C), while IL-1ß mRNA 
expression was also significantly attenuated by both 
the GF9-HDL and GA/E31-HDL formulations in 
the alcohol-fed as well as in the PF groups (Fig. 1D). 
MIP-1α mRNA levels were increased in alcohol-fed 
mice, but TREM-1 blockade with GF9-HDL or 
GA/E31-HDL significantly attenuated this increase 
compared to the vehicle control (Fig. 1E). Regulated 
on activation, normal T cell expressed, and secreted 
(RANTES) mRNA levels did not change regardless of 
alcohol feeding or TREM-1 treatment (Fig. 1F).
Next, we used specific ELISA kits to assess the 
protein levels of cytokines in the serum and in whole-
liver lysates (Fig. 2). We found a significant increase 
in MCP-1 level in the serum and liver and TNF-α in 
the liver of alcohol-fed mice compared to PF controls 
(Fig. 2A-D). All these alcohol-induced increases were 
prevented both in the serum and liver by administra-
tion of either TREM-1 inhibitor. Interestingly, we 
found attenuation of alcohol-induced liver MCP-1 
and TNF-α induction even in the vehicle-treated 
(HDL only) groups (Fig. 2A-C). The increase in total 
IL-1ß levels after alcohol feeding and its attenuation 
by TREM-1 inhibition did not reach statistical signif-
icance (Fig. 2D).
Because TREM-1 is a membrane-associated mol-
ecule that triggers SYK activation as one of its prox-
imal signaling molecules and we previously found 
increased SYK phosphorylation in liver in ALD,(24) we 
tested the levels of total and activated phospho-SYK 
(p-SYKY525/526) in the livers. We found significantly 
increased total and p-SYKY525/526 levels after alco-
hol feeding (Fig. 2E-G). Treatment with GA/E31-
HDL significantly decreased the p-SYKY525/526 levels 
in alcohol-fed mice compared to the untreated and 
vehicle-treated alcohol-fed groups, while GF9-HDL 
decreased p-SYKY525/526 levels compared to the vehi-
cle-treated group. (Fig. 2E,F).
BloCKaDe oF trem-1  
aCtiVation reDuCes 
eXpression oF maCropHage 
anD neutropHil marKers in 
liVer
In agreement with previous studies indicating 
that chronic alcohol use causes hepatic macrophage 
infiltration and activation,(1,3,26) we found increased 
expression of the Kupffer cell/macrophage mark-
ers F4/80 and CD68 at the mRNA level. Treatment 
with the TREM-1 inhibitors significantly attenuated 
alcohol-induced expression of both F4/80 and CD68 
in the liver, indicating anti-inflammatory effects 
(Fig. 3A,B). We also found a significant decrease in 
F4/80 expression on paraffin-embedded liver sections 
by IHC in alcohol-fed mice treated with either GF9-
HDL or GA/E31-HDL compared to the EtOH-fed 
vehicle-treated group (Fig. 3C,D).
Neutrophil infiltration of the liver is a characteristic 
of alcoholic hepatitis; therefore, we investigated mark-
ers associated with this cell population. Expression of 
the neutrophil markers Ly6G and MPO were signifi-
cantly increased in livers of alcohol-fed mice compared 
to PF controls. This was fully prevented by TREM-1 
blockade (Fig. 3E,F). Interestingly, the HDL vehi-
cle alone also resulted in a decreasing trend of Ly6G 
and MPO expression in alcohol-fed mice; how-
ever, the GF9-HDL and GA/E31-HDL TREM-1 
inhibitors significantly attenuated Ly6G and MPO 
levels even when compared to the vehicle-treated 
alcohol-fed mice (Fig. 3E,F). MPO staining on IHC 
confirmed that both TREM-1 inhibitors significantly 
reduced MPO-positive cell numbers compared to the 
untreated alcohol-fed control group (Fig. 3G,H).
trem-1 inHiBitory 
Formulations anD HDl 
ameliorate CHroniC 
alCoHol-inDuCeD liVer 
inJury anD steatosis
Next, we evaluated the impact of the TREM-1 
inhibitors on hepatocyte damage and steatosis in 
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Fig. 1. Impact of TREM-1 pathway inhibition on TREM-1 and inflammatory cytokine mRNA expression. [Correction made 31 October, 
2018. The table title was modified to the correct description.] TREM-1 pathway inhibition suppresses the expression of (A) TREM-1 
and inflammatory cytokines (B) MCP-1, (C) TNF-α, (D) IL-1β, and (E) MIP-1α but not (F) RANTES at the mRNA level as measured 
in whole-liver lysates by real-time quantitative PCR. * indicates significance level compared to nontreated PF group; # indicates significance 
level compared to nontreated alcohol-fed group; o indicates significance level compared to vehicle-treated alcohol-fed group. Significance 
levels are as follows: */#/oP ≤ 0.05; **/##/ooP ≤ 0.01; ***/oooP ≤ 0.001; ****P ≤ 0.0001. Abbreviation: CCL, chemokine (C-C motif) ligand.
tornai et al. Hepatology CommuniCations, January 2019
106
Fig. 2. TREM-1 blockade and protein levels of inf lammatory pathway molecules. [Correction made 31 October, 2018. The table 
title was modified to the correct description.] TREM-1 blockade reduces inf lammatory cytokine levels in (A) serum and (B-D) 
whole-liver lysates as measured with specific ELISA kits. (E-G) Total liver protein was analyzed for total SYK and activated 
p-SYKY525/526 expression by western blotting using β-actin as a loading control. Statistical analysis was performed by evaluating two 
blots (n = 4/group). * indicates significance level compared to the nontreated PF group; # indicates significance level compared to the 
nontreated alcohol-fed group; o indicates significance level compared to the vehicle-treated alcohol-fed group. Significance levels 
are as follows: */#/oP ≤ 0.05; **/##P ≤ 0.01; ***P ≤ 0.001; ****/####P ≤ 0.0001.
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Fig. 3. TREM-1 inhibition and markers of immune cell infiltration. [Correction made 31 October, 2018. The table title was 
modified to the correct description.] (A,B) TREM-1 inhibition suppresses the mRNA expression of macrophage cell markers in the 
liver as measured by real-time quantitative PCR. (C,D) Both TREM-1 inhibitors attenuated F4/80 as shown by IHC. (E,F) TREM-1 
inhibition suppresses the mRNA expression of neutrophil cell markers in the liver as measured by real-time quantitative PCR. (G,H) 
Both TREM-1 inhibitors attenuated MPO-positive cell infiltration as shown by IHC. * indicates significance level compared to the 
nontreated PF group; # indicates significance level compared to the nontreated alcohol-fed group; o indicates significance level compared 
to the vehicle-treated alcohol-fed group. Significance levels are as follows: */#/oP ≤ 0.05; **/##P ≤ 0.01; ###P ≤ 0.001; ****/####P ≤ 0.0001.
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liver. Serum ALT levels obtained during week 5 
of the alcohol feeding showed significant increases 
in alcohol-fed mice compared to PF controls. This 
ALT increase was attenuated in both TREM-1 
inhibitor-treated groups, indicating attenuation of 
liver injury (Fig. 4A). Interestingly, vehicle treat-
ment (HDL) also showed a similar protective effect 
(Fig. 4A).
Consistent with steatosis, we found a significant 
increase in Oil Red O staining in livers of alcohol-fed 
mice compared to PF controls (Fig. 4C). Oil Red O 
(Fig. 4B-D) and H&E (Fig. 4D) staining revealed 
attenuation of steatosis in the alcohol-fed TREM-1 
inhibitor-treated mice compared to both untreated 
and vehicle (HDL)-treated alcohol-fed groups 
(Fig. 4B-D).
To further assess the effects of the TREM-1 inhib-
itors on mechanisms of lipid metabolism, we tested 
genes involved in lipid synthesis (sterol regulatory 
element binding transcription factor 1 [SREBF1] 
and acetyl-coenzyme A carboxylase 1 [ACC1]) 
along with the lipid accumulation marker perilipin-2 
(ADRP) (Fig. 5A-C). Both TREM-1 inhibitors but 
not vehicle treatment prevented alcohol-induced 
up-regulation of SREBF1, ACC1, and ADRP at 
the mRNA level (Fig. 5A-C). To assess lipid oxi-
dation, we tested peroxisome proliferator-activated 
receptor α (PPARα), carnitine palmitoyl transferase 
1A (CPT1A), and medium-chain acyl-coenzyme A 
dehydrogenase (MCAD) mRNA levels in whole-
liver samples (Fig. 5D-F). Alcohol feeding signifi-
cantly reduced mRNA expression of PPARα and 
CPT1A, while MCAD had a decreasing trend. Both 
TREM-1 inhibitors as well as the vehicle treatment 
significantly increased PPARα and MCAD lev-
els compared to the untreated alcohol-fed controls 
(Fig. 5D-F).
trem-1 BloCKaDe 
ameliorates eXpression oF 
early FiBrosis marKer genes 
inDuCeD By CHroniC alCoHol 
Consumption
The clinical progression of ALD is associated with 
liver fibrosis.(27) Our mouse model of ALD mimics the 
early phase of the human disease, yet mRNA levels 
of early fibrosis markers Pro-Col1α and α-SMA were 
significantly increased in alcohol-fed mice compared 
to PF controls in the whole-liver samples (Fig. 6A,B). 
Induction of these makers was remarkably attenuated 
in the vehicle-treated group and, importantly, further 
decreased by the TREM-1 inhibitory formulations 
used (Fig. 6A,B).
QuantitatiVely similar 
maCropHage enDoCytosis 
oF gF9-HDl anD ga/e31-HDl is 
mainly meDiateD By sr-a
We studied the uptake of GF9-HDL and GA/
E31-HDL in vitro in order to evaluate potential 
mechanisms of targeted delivery of GF9 (GA/E31). 
Kupffer cells and recruited hepatic macrophages 
express high levels of SRs, including SR-A, that are 
involved in phagocytosis and removal of oxidatively 
damaged lipoproteins and cells from the blood circu-
lation.(28,29) We previously demonstrated intracellu-
lar macrophage delivery of GF9, GA31, and GE31 
by macrophage-targeted GF9-HDL and GA/E31-
HDL, respectively, and hypothesized that the observed 
macrophage endocytosis of these complexes is SR 
mediated.(16,17) To further investigate the molecular 
mechanisms involved in this process, we used J774 
macrophages as a model for Kupffer cells and incu-
bated them with rho B-labeled GF9-HDL or GA/
E31-HDL in the presence or absence of cytochalasin 
D, fucoidan, or BLT-1, which are known to inhibit all 
SRs,(30) SR-A,(31) or SR-BI,(32) respectively.
In the presence of cytochalasin D, which inhibits 
both SR-A and SR-BI, the macrophage uptake of 
both TREM-1 inhibitor complexes was significantly 
inhibited, suggesting that this uptake is SR medi-
ated. Fucoidan, an SR-A inhibitor, substantially sup-
pressed endocytosis of TREM-1 inhibitor complexes 
at 22 hours but not at 4 hours, indicating time-de-
pendent mechanisms of SR-A-mediated endocytosis 
(Fig. 7B). In contrast, BLT-1, which inhibits SR-BI, 
similarly inhibited the uptake of the complexes at both 
time points but to a lesser extent compared with that 
of fucoidan (Fig. 7C), presumably because of lower 
expression of SR-BI on J774 macrophages.(33) These 
findings suggest that SR-A is the main contributor 
in SR-mediated endocytosis of both GF9-HDL and 
GA/E31-HDL.
Interestingly, quantitatively determined macrophage 
uptake levels in the presence or absence of fucoidan 
or BLT-1 were similar for GF9-HDL and GA/
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Fig. 4. Liver damage after 5 weeks of alcohol feeding and effect of TREM-1 pathway inhibition in a mouse model of ALD. Cheek blood 
and livers were harvested at death. (A) Serum ALT levels were measured using a kinetic method. (B-D) Liver sections were stained with 
(B,C) Oil Red O and (D) H&E staining, and the lipid content was analyzed by ImageJ (B). * indicates significance level compared to the 
nontreated PF group; # indicates significance level compared to the nontreated alcohol-fed group; o indicates significance level compared 
to the vehicle-treated alcohol-fed group. Significance levels are as follows: */oP ≤ 0.05; ##/ooP ≤ 0.01;***/###P ≤ 0.001; ****P ≤ 0.0001.
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Fig. 5. TREM-1 inhibition alters mRNA expression of enzymes involved in lipid metabolism. mRNA expression of genes involved 
in (A,B) lipid synthesis (SERBF1, ACC1), (D-F) lipid oxidation (PPARα, CPT1A, MCAD), and (C) the lipid accumulation marker 
(ADRP) were measured in whole liver. [Correction made 31 October, 2018. The table title and label descriptions included the wrong 
information and have been modified.] * indicates significance level compared to the nontreated PF group; # indicates significance 
level compared to the nontreated alcohol-fed group; o indicates significance level compared to the vehicle-treated alcohol-fed group. 
Significance levels are as follows: */#/oP ≤ 0.05; **/##/ooP ≤ 0.01; ###P ≤ 0.001; ****P ≤ 0.0001.
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E31-HDL (Fig. 7). This importantly suggests that the 
combination of GF9 and apo A-I peptide sequences 
in GA31 and GE31 sequences does not change the 
level and mechanisms of macrophage endocytosis of 
GA/E31-HDL compared with those of GF9-HDL.
Discussion
In this study, we report for the first time an import-
ant role for TREM-1 in ALD. Using a mouse model, 
we found a significant up-regulation of TREM-1 
in livers of mice following chronic alcohol feeding. 
Treatment with novel ligand-independent TREM-1 
inhibitors reduced the expression of the TREM-1 
molecule itself, attenuated or fully prevented alco-
hol-induced increases in proinflammatory cytokines 
at the mRNA level, and inhibited SYK activation. 
We demonstrated that TREM-1 blockade results 
in reduced macrophage and neutrophil infiltration 
and activation indicated by reduced F4/80, CD68, 
Ly6G, and MPO expression in the liver. These find-
ings complement our previous data demonstrating 
that TREM-1 blockade using GF9-HDL and GA/
E31-HDL suppresses macrophage infiltration of the 
tumor in cancer mice.(17) The TREM-1 inhibitors 
attenuated alcohol-induced liver steatosis. HDL and 
the TREM-1 inhibitors also attenuated liver injury 
and markers of early fibrosis in alcohol-fed mice. 
Interestingly, the HDL vehicle control showed similar 
efficiency as the inhibitory formulations at the protein 
level of the proinflammatory cytokines. We discovered 
that HDL has some protective effects on ALD at the 
level of ALT and lipid oxidation.
While the ligand of TREM-1 is still unknown, it 
has been shown that TREM-1 activation amplifies 
inflammation and synergizes with TLR signaling path-
ways.(34) It was also observed that bacterial infection 
and challenge with LPS or lipoteichoic acid increase 
TREM-1 expression,(7) indicating a positive feed-
back loop among PAMP exposure, TREM-1 expres-
sion, and inflammatory cytokine induction. Different 
DAMPs, such as high-mobility group box protein 
1 [Correction made 31 October, 2018. The correct 
protein was noted.] and heat shock protein 70, have 
been suggested to stimulate TREM-1,(35) while other 
studies found cell (granulocyte and platelet)-surface- 
associated activators as well.(35,36) Both PAMPs and 
DAMPs are present in ALD, providing potential 
mechanisms for TREM-1 up-regulation in this dis-
ease. Alcohol induces changes in the gut microbiome 
and disrupts the gut barrier function, resulting in 
increased levels of endotoxin and microbial PAMPs in 
circulation.(1,37) Alcohol also causes hepatocyte dam-
age that leads to the release of DAMPs,(23) and all 
these processes contribute to TREM-1 activation.
Fig. 6. TREM-1 inhibition suppresses the expression of fibrinogenesis marker molecules. (A) Pro-Col1α and (B) α-SMA are suppressed 
by TREM-1 blockade at the RNA level as measured in whole-liver lysates. [Correction made 31 October, 2018. The label descriptions 
included the wrong description and have been modified.] * indicates significance level compared to the nontreated PF group; # indicates 
significance level compared to the nontreated alcohol-fed group; o indicates significance level compared to the vehicle-treated alcohol-fed 
group. Significance levels are as follows: */#/oP ≤ 0.05; ##P ≤ 0.01; ****/####P ≤ 0.0001. Data are presented as mean ± SEM.
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TREM-1 signaling leads to phosphorylation and 
activation of SYK, which has been indicated as a 
major regulator in inflammatory processes in ALD.(38) 
TREM-1 also amplifies TLR4 signaling that involves 
downstream SYK activation and phosphorylation.(38) 
Indeed, we found increased total and phosphorylated 
Fig. 7. Scavenger receptors SR-A and SR-BI mediate the macrophage uptake of GF9-HDL and GA/E31-HDL. (A) Schematic 
representation for the proposed role of TREM-1 signaling in ALD and the SCHOOL mechanism of TREM-1 blockade. (A, left 
panel) Activation of the TREM-1/DAP12 receptor complex expressed on Kupffer cells leads to phosphorylation of the DAP12 
cytoplasmic signaling domain, subsequent SYK recruitment, and the downstream inflammatory cytokine response. (A, right panel) 
SR-mediated endocytosis of HDL-bound GF9 peptide inhibitors by Kupffer cells results in the release of GF9 (GA31 or GE31) into 
the cytoplasm; GF9 self-penetrates the cell membrane and blocks intramembrane interactions between TREM-1 and DAP12, thereby 
preventing DAP12 phosphorylation and the downstream signaling cascade. (B,C) Macrophage uptake of GF9-HDL and GA/E31-
HDL in vitro is SR mediated in a time-dependent manner and is largely driven by SR-A. As described in the Materials and Methods, 
J774 macrophages were cultured at 37°C overnight with medium. Prior to uptake of GF9-HDL and GA/E31-HDL, cells were treated 
for 1 hour at 37°C with 40 µM cytochalasin D and either (B) 400 µg/mL fucoidan or (C) 10 µM BLT-1, as indicated. Cells were then 
incubated for either 4 hours or 22 hours with medium containing 2 µM rho B-labeled GF9-HDL (gray bars) or GA/E31-HDL (black 
bars), respectively. Cells were lysed, and rho B f luorescence intensities of lysates were measured and normalized to the protein content. 
Results are expressed as mean ± SEM (n = 3); *P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001 versus uptake of GF9-HDL and GA/E31-HDL 
in the absence of inhibitor. Abbreviations: D, DAP12; DAP12, DNAX activation protein of 12 kDa; K, Kupffer cell; RFU, relative 
f luorescence units; SCHOOL, signaling chain homo-oligomerization.
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SYK levels in the livers of alcohol-fed mice that was 
attenuated by TREM-1 inhibitor administration. A 
previous study showed that inhibition of SYK acti-
vation attenuates alcohol-induced liver inflamma-
tion, cell death, and steatosis, suggesting that the 
SYK pathway could be a feasible therapeutic target 
in ALD.(24) SYK is expressed in a wild spectrum of 
cells, while TREM-1 inhibition may specifically 
modulate macrophages, neutrophils, and stellate cells 
that each play a role in ALD. Another advantage of 
TREM-1 inhibition is that it likely attenuates signal-
ing from a broader spectrum of TLRs, not only TLR4.
TREM-1 activation alone has been shown to increase 
the production of proinflammatory chemokines and 
cytokines.(39) Furthermore, simultaneous stimulation 
of TREM-1 and TLRs by an agonistic anti-TREM-1 
antibody and different TLR ligands synergized in 
the induction of these proinflammatory molecules. 
TREM-1 and TLR4 costimulated monocytes showed 
increased production of MCP-1, IL-1β, and IL-8. In 
contrast, the level of the anti-inflammatory cytokine 
IL-10 decreased when anti-TREM-1 antibody and 
the TLR3 ligand poly(I:C) or the TLR4 ligand LPS 
simultaneously attached to their receptors.(40) Because 
self-perpetuating proinflammatory pathways are pres-
ent in alcoholic hepatitis, interruption of these path-
ways using TREM-1 inhibition seems attractive.
By inducing TNF-α, IL-6, MCP-1, IL-8, and 
granulocyte-macrophage colony-stimulating factor and 
inhibiting IL-10 production, TREM-1 is involved in 
activation and recruitment of monocytes and mod-
ulation of inflammatory responses.(40) Furthermore, 
TREM-1 expression was highly up-regulated on the 
surface of infiltrating monocytes and neutrophils in 
human tissues infected by bacteria, highlighting the 
importance of this receptor in these processes.(7) In alco-
holic hepatitis, neutrophils infiltrate the liver, inducing 
oxidative stress and cytotoxicity that contributes to the 
high mortality of the disease.(2) We showed that these 
processes can be attenuated by TREM-1 inhibitors. 
Mechanistically, the GF9-HDL and GA/E31-HDL 
formulations target the liver more efficiently than only 
the peptides alone and release the TREM-1 inhibitory 
sequences inside the target cells where these peptides 
likely inhibit TREM-1 signaling by disrupting the 
intramembrane interactions of the TREM-1 receptor 
and its signaling adaptor molecule DNAX activation 
protein of 12kDa [Correction made 31 October, 2018. 
The correct protein was noted.] (Fig. 7).(15-17)
We previously hypothesized that the observed pref-
erential endocytosis of GF9-HDL and GA/E31-HDL 
by macrophages and hepatic clearance of these com-
plexes are mediated by SR recognition of putative epi-
topes in the modified apo A-I peptide constituents of 
GF9-HDL and GA/E31-HDL.(16,17,19) Our current 
findings indicate that GF9-HDL and GA/E31-HDL 
are largely recognized by SR-A on macrophages (Fig. 7). 
We also observed SR-BI-mediated uptake, which 
likely explains the previously observed hepatic clear-
ance for these complexes in another animal model.(19) 
While these data confirm our hypothesis, future stud-
ies are needed to determine the clearance properties 
for GF9-HDL and GA/E31-HDL in ALD.
Further, our present study demonstrates that GF9-
HDL and GA/E31-HDL exhibit not only similar 
macrophage uptake in vitro largely driven by SR-A 
(Fig. 7) but also similar therapeutic effect in a mouse 
model of ALD (Figs. 1-2). This is in line with our pre-
vious studies where GF9-HDL and GA/E31-HDL 
exhibited similar therapeutic activities in cancer and 
arthritic mice.(16,17) We suggest that SR-A epitopes 
are similarly exposed on GA31 and GE31 in GA/
E31-HDL and on PA22 and PE22 in GF9-HDL, 
providing similar uptake of these complexes and as 
a result delivery of TREM-1 inhibitory GF9 pep-
tide sequences in vivo. The use of GA/E31-HDL in 
the further development of effective and low-toxicity 
therapy for ALD is advantageous because it makes the 
entire manufacturing process easier and less expensive. 
We also suggest that the in vitro macrophage uptake 
assay can be potentially used to predict the outcomes 
for macrophage-targeted TREM-1 therapy in vivo.
In addition to attenuating inflammatory processes, 
the TREM-1 inhibitory formulations also amelio-
rated hepatocyte damage and steatosis. Serum ALT 
and liver triglyceride levels were both decreased in 
the GF9-HDL, GA/E31-HDL, and HDL-vehicle 
treated groups. The vehicle also had an inhibitory 
effect on TNF-α and MCP-1 protein levels as well 
as on mRNA expression of neutrophil and fibrosis 
markers, indicating that the HDL vehicle formulation 
can attenuate inflammation to a moderate extent. A 
previous study found evidence that HDL can protect 
hepatocytes from endoplasmic reticulum stress,(41) 
while other publications reported a scavenger function 
of HDL for LPS and lipoteichoic acid(42,43) that 
could prevent immune cells from being activated by 
those molecules.(42,43) Further, the observed moderate 
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beneficial effect of HDL treatment alone on fatty 
acid oxidation markers in alcohol-exposed mice (Fig. 
5A-C) is in line with data that demonstrate infusion 
of reconstituted HDL reduces fatty acid oxidation in 
patients with type 2 diabetes mellitus.(44) In human 
and rat plasma, apo A-I, the major protein of HDL, 
has been shown to inhibit lipid peroxidation.(45) These 
data might provide an explanation for our findings of 
the hepatoprotective effects of HDL.
Our study shows that TREM-1 inhibitors with HDL 
formulation exerted significant inhibition on early sig-
naling events of proinflammatory processes at the level 
of cytokine mRNA and the activated p-SYK protein 
levels compared to the HDL vehicle alone in a mouse 
model of ALD. This effect presumably would be even 
more obvious at the protein level of cytokines in a more 
severe liver injury. However, in mice, the most commonly 
used 5-week alcohol feeding that we used resulted in 
moderate liver damage and minimal inflammation,(25) 
which is a limitation of our study. Importantly, as shown 
on the stained liver sections, the GF9-HDL and GA/
E31-HDL formulations significantly inhibited immune 
cell infiltration and steatosis compared to the HDL 
vehicle only group [Correction made 31 October, 2018. 
The word group was added.] in mice with ALD. Thus, 
exploration of TREM-1 inhibitors in decreasing inflam-
mation deserves further investigation in ALD.
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